Jeffrey Crawford Selected Research

pegfilgrastim (Neulasta)

10/2022	A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices.
7/2022	A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis.
5/2021	Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety.
1/2021	Use of prophylactic pegfilgrastim for chemotherapy-induced neutropenia in the US: A review of adherence to present guidelines for usage.
10/2013	Myeloid growth factors.
6/2007	A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer.
4/2006	Risk assessment and guidelines for first-cycle colony-stimulating factor use in the management of chemotherapy-induced neutropenia.
7/2005	A combined analysis of average relative dose intensity in the chemotherapy of solid tumors with pegfilgrastim or filgrastim support.
8/2003	Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia.
8/2003	Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jeffrey Crawford Research Topics

Disease

78	Neoplasms (Cancer) 10/2022 - 01/2002
33	Febrile Neutropenia 10/2022 - 01/2002
29	Neutropenia 01/2022 - 01/2002
24	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 10/2002
21	Lung Neoplasms (Lung Cancer) 10/2022 - 02/2002
15	Breast Neoplasms (Breast Cancer) 07/2022 - 09/2002
12	Anemia 01/2021 - 02/2002
11	Infections 01/2021 - 01/2002
10	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 03/2016 - 12/2004
9	Leukemia 01/2017 - 09/2002
8	Lymphoma (Lymphomas) 10/2015 - 08/2003
7	Non-Hodgkin Lymphoma (Lymphosarcoma) 10/2022 - 07/2003
6	Disease Progression 01/2021 - 04/2005
6	Thrombocytopenia (Thrombopenia) 01/2021 - 10/2002
5	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 10/2007
5	Fatigue 01/2021 - 09/2002
4	Adenocarcinoma 06/2022 - 12/2009
4	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 10/2007
2	Hemorrhage 01/2021 - 05/2015
2	Hematologic Neoplasms (Hematological Malignancy) 01/2021 - 01/2006
2	Neoplasm Metastasis (Metastasis) 01/2020 - 10/2003
2	Inflammation (Inflammations) 01/2017 - 05/2016
2	Esophagitis 01/2017 - 10/2002
2	Adenocarcinoma of Lung 06/2012 - 12/2009
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 06/2010 - 09/2002
1	COVID-19 01/2022
1	Alopecia (Baldness) 01/2021
1	Nausea 01/2021
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2021
1	Thrombocytopenia 1 01/2021
1	Dyspnea (Shortness of Breath) 01/2021
1	Vomiting 01/2021
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2021
1	Carcinoma (Carcinomatosis) 01/2021
1	Epilepsy (Aura) 01/2020
1	Psychotic Disorders (Schizoaffective Disorder) 01/2019
1	Chronic Renal Insufficiency 09/2018
1	Sarcoma (Soft Tissue Sarcoma) 01/2018

Drug/Important Bio-Agent (IBA)

14	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 10/2022 - 01/2002
14	Filgrastim (Neupogen)FDA Link 10/2022 - 01/2002
13	PlatinumIBA 02/2020 - 01/2003
12	pegfilgrastim (Neulasta)FDA Link 10/2022 - 01/2002
12	Colony-Stimulating Factors (Colony Stimulating Factor)IBA 01/2015 - 08/2003
10	Carboplatin (JM8)FDA LinkGeneric 01/2021 - 11/2004
9	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 12/2017 - 12/2003
8	Hemoglobins (Hemoglobin)IBA 10/2014 - 08/2002
6	Paclitaxel (Taxol)FDA LinkGeneric 12/2013 - 10/2002
5	HematinicsIBA 09/2018 - 06/2009
5	ErbB Receptors (EGF Receptor)IBA 12/2013 - 01/2003
4	Erythropoietin FDA Link 09/2018 - 02/2002
4	Panitumumab (Vectibix)FDA Link 01/2018 - 01/2008
4	Biomarkers (Surrogate Marker)IBA 01/2017 - 01/2010
4	Cisplatin (Platino)FDA LinkGeneric 05/2015 - 10/2002
4	Etoposide (VP 16)FDA LinkGeneric 05/2015 - 08/2003
4	Anti-Bacterial Agents (Antibiotics)IBA 01/2015 - 01/2005
4	Monoclonal AntibodiesIBA 12/2013 - 03/2004
3	AnthracyclinesIBA 02/2011 - 11/2005
3	Vinorelbine (Navelbine)FDA LinkGeneric 06/2007 - 10/2002
3	Epoetin Alfa (Epogen)FDA Link 03/2007 - 02/2002
2	B7-H1 AntigenIBA 06/2022 - 01/2021
2	Phosphotransferases (Kinase)IBA 10/2019 - 01/2003
2	ostarineIBA 01/2018 - 01/2016
2	IpilimumabIBA 12/2017 - 01/2016
2	Sunitinib (Sutent)FDA Link 03/2016 - 05/2015
2	IronIBA 05/2014 - 07/2005
2	Pharmaceutical PreparationsIBA 10/2013 - 01/2003
2	Tyrosine Kinase InhibitorsIBA 06/2012 - 01/2003
2	Darbepoetin alfa (Aranesp)FDA Link 06/2012 - 06/2009
2	Thalidomide (Thalomid)FDA Link 12/2006 - 10/2006
2	Docetaxel (Taxotere)FDA Link 11/2006 - 01/2003
2	Topotecan (Hycamtin)FDA LinkGeneric 01/2006 - 11/2005
2	Tyrosine (L-Tyrosine)FDA Link 03/2004 - 01/2003
2	lipid-associated sialic acid (LASA)IBA 08/2002 - 02/2002
1	Biosimilar PharmaceuticalsIBA 10/2022
1	ORALIT (ORS)IBA 01/2021
1	folfirinoxIBA 01/2021
1	Recombinant DNA (Recombinant DNA Research)IBA 01/2021
1	Dietary Fiber FDA Link 01/2021
1	Dietary Carbohydrates (Carbohydrate, Dietary)IBA 01/2021
1	durvalumabIBA 01/2021
1	tremelimumabIBA 01/2021
1	CarbohydratesIBA 01/2021
1	osimertinibIBA 01/2020
1	2- (3- (2- (1- isopropyl- 3- methyl- 1H- 1,2- 4- triazol- 5- yl)- 5,6- dihydrobenzo(f)imidazo(1,2- d)(1,4)oxazepin- 9- yl)- 1H- pyrazol- 1- yl)- 2- methylpropanamideIBA 10/2019
1	Phosphatidylinositol 4,5-Diphosphate (Phosphatidylinositol 4,5 Diphosphate)IBA 10/2019
1	Polytetrafluoroethylene (Teflon)FDA Link 01/2019
1	Everolimus FDA Link 01/2018

Therapy/Procedure

87	Drug Therapy (Chemotherapy) 10/2022 - 01/2002
31	Therapeutics 01/2021 - 02/2002
13	Radiotherapy 01/2017 - 10/2002
10	Drug Tapering 05/2021 - 01/2004
6	Adjuvant Chemotherapy 06/2013 - 12/2003
4	Induction Chemotherapy 12/2013 - 10/2002
3	Length of Stay 01/2022 - 05/2006
3	Erythrocyte Transfusion 10/2014 - 10/2013
3	Chemoradiotherapy 12/2013 - 10/2002
3	Treatment Delay 10/2013 - 11/2004
2	Immunotherapy 01/2021 - 06/2019
2	Combination Drug Therapy (Combination Chemotherapy) 10/2005 - 07/2005
1	Ambulatory Care (Outpatient Care) 01/2022